Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma

Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma. It is not known if there are differences in outcome between early versus delayed BEV treatment of recurrent glioblastoma. We examined the relationship between the time of starting BEV treatment and outcomes in pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurooncol
Main Authors: Hamza, Mohamed A., Mandel, Jacob J., Conrad, Charles A., Gilbert, Mark R., Yung, W. K. Alfred, Puduvalli, Vinay K., DeGroot, John F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297475/
https://ncbi.nlm.nih.gov/pubmed/24803001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1460-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados